Small Methods. 2024 Jan 2:e2301310(IF:25.367).

本文采用的英格恩产品: Entranster-H4000

An Inducible CRISPR-dCas9-Based Transcriptional Repression System for Cancer Therapy

Affiliations

Affiliations

  • 1 Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, 300060, China.
  • 2 Department of Orthopedics, Tianjin University Tianjin Hospital, Tianjin, 300211, China.
  • 3 Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, Tianjin, 300121, China.
  • 4 Tianjin Key Laboratory of General Surgery in construction, Tianjin Union Medical Center, Tianjin, 300121, China.

Abstract

Gene therapy has been adapted for improving malignant tumor treatment. However, pharmacotherapies targeting cancer remain limited and are generally inapplicable for rare disease patients. Oleanolic acid (OA) is a plant-derived triterpenoid that is frequently used in Chinese medicine as a safe but slow-acting treatment for many disorders. Here, the congruent pharmacological activities of OA and CRISPR-dCas9 in targeting AURKA or KDM1A and improving disease-specific prognosis and used a synthetic-biology-inspired design principle to engineer a therapeutic gene circuit that enables a concerted action of both drugs are utilized. In particular, the OA-triggered CRISPR-dCas9 transcriptional repression system rapidly and simultaneously attenuated lung and thyroid cancer. Collectively, this work shows that rationally engineered synthetic gene circuits are capable of treating multifactorial diseases in a synergistic manner by multiplexing the targeting efficiencies of single therapeutics.

Keywords: CRISPR-dCas9; cancer therapy; oleanolic acid; transcription regulation.

在线客服
在线客服
热线电话
 
0
    0
    我的购物车
    购物车是空的去下单